PSY2/YNL201C Literature Guide Help

Other names published for PSY2: YNL201C

PSY2 - Primary Literature (10)

ReferenceOther Genes Addressed
Oler AJ and Cairns BR  (2012) PP4 dephosphorylates Maf1 to couple multiple stress conditions to RNA polymerase III repression. EMBO J 31(6):1440-52
Falk JE, et al.  (2010) A Mec1- and PP4-dependent checkpoint couples centromere pairing to meiotic recombination. Dev Cell 19(4):599-611
Vazquez-Martin C, et al.  (2008) Characterization of the role of a trimeric protein phosphatase complex in recovery from cisplatin-induced versus noncrosslinking DNA damage. FEBS J 275(16):4211-21
Grandin N and Charbonneau M  (2007) Mrc1, a non-essential DNA replication protein, is required for telomere end protection following loss of capping by Cdc13, Yku or telomerase. Mol Genet Genomics 277(6):685-99
O'Neill BM, et al.  (2007) Pph3-Psy2 is a phosphatase complex required for Rad53 dephosphorylation and replication fork restart during recovery from DNA damage. Proc Natl Acad Sci U S A 104(22):9290-5
Hastie CJ, et al.  (2006) The Saccharomyces cerevisiae orthologue of the human protein phosphatase 4 core regulatory subunit R2 confers resistance to the anticancer drug cisplatin. FEBS J 273(14):3322-34
Keogh MC, et al.  (2006) A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature 439(7075):497-501
Gingras AC, et al.  (2005) A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics 4(11):1725-40
O'Neill BM, et al.  (2004) Coordinated functions of WSS1, PSY2 and TOF1 in the DNA damage response. Nucleic Acids Res 32(22):6519-30
Wu HI, et al.  (2004) Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer Res 64(11):3940-8